{
  "claim_id": "claim_005",
  "claim": "Flublok (quadrivalent) was evaluated in the pivotal trial against Fluarix (quadrivalent standard-dose vaccine).",
  "document": "Liu_et_al.__2024_",
  "additional_evidence_check": {
    "checked_for_more": true,
    "found_additional": true,
    "additional_count": 4
  },
  "completeness_stats": {
    "existing_evidence": 5,
    "new_evidence_found": 4,
    "total_evidence": 8
  },
  "combined_evidence": [
    {
      "id": 1,
      "quote": "In this randomized trial (Clinical trials gov: NCT03722589), sera pre- and post vaccination with quadrivalent inactivated egg based (IIV4), cell culture based (ccIIV4), and recombinant (RIV4) influenza",
      "relevance_explanation": "This quote explicitly states that the randomized trial evaluated quadrivalent recombinant influenza vaccine (RIV4, which is Flublok), alongside quadrivalent inactivated egg-based (IIV4) and cell culture-based (ccIIV4) vaccines, confirming that Flublok (quadrivalent) was evaluated in the pivotal trial."
    },
    {
      "id": 2,
      "quote": "Enrolled and Randomized n=723 vaccine Allocation Flu zone IIV4 n=122 18-44 years: n=57 45-64 years: n=65 Completed day 0 (n=110) 1 month (n=110) and 6 months (n=101) visit Fluarix IIV4 n=120 18-44 years: n=55 45-64 years: n=65 Completed day 0 (n=120) 1 month (n=118) and 6 months (n=107) visit re-enrolled in Year 2 and new enrollees randomized n=684 (139*) ccIIV4 in Year 1 n=214 RIV4 in Year 1 n=152",
      "relevance_explanation": "This quote provides the actual allocation of participants to the Fluarix IIV4 (quadrivalent standard-dose vaccine) and RIV4 (Flublok quadrivalent), showing that both vaccines were directly compared in the pivotal trial."
    },
    {
      "id": 3,
      "quote": "sera pre- and post vaccination with quadrivalent inactivated egg based (IIV4), cell culture based (ccIIV4), and recombinant (RIV4) influenza",
      "relevance_explanation": "This quote confirms that the study included both the recombinant quadrivalent vaccine (Flublok) and the standard quadrivalent inactivated vaccine (IIV4, which includes Fluarix), supporting the claim of a direct evaluation."
    },
    {
      "id": 4,
      "quote": "Fluarix IIV4: Day 0 (n = 55), 1 m (n = 55), 6 m (n = 48); ccIIV4: Day 0 (n = 133), 1 m (n = 132), 6 m (n = 124); RIV4: Day 0 (n = 98), 1 m (n = 98), 6 m (n = 85);",
      "relevance_explanation": "This quote lists the sample sizes for Fluarix IIV4 (standard-dose quadrivalent), ccIIV4, and RIV4 (Flublok quadrivalent), demonstrating that Flublok was evaluated against Fluarix in the trial."
    },
    {
      "id": 5,
      "quote": "Fluarix IIV4: Day 0 (n = 24), 1 m (n = 24), 6 m (n = 23); ccIIV4: Day 0 (n = 56), 1 m (n = 54), 6 m (n = 51); RIV4: Day 0 (n = 40), 1 m (n = 40), 6 m (n = 38).",
      "relevance_explanation": "This quote further confirms that Flublok (RIV4) and Fluarix (IIV4) were both included as arms in the pivotal trial, supporting the claim of their direct evaluation."
    },
    {
      "id": "comp_1",
      "quote": "acell culture based influenza vaccine (Flu cel vax Quadrivalent by Seqirus, Inc., ccIIV4) and a recombinant influenza vaccine (Flublok Quadrivalent by Sanofi Pasteur, RIV4). RIV4 contains 3 times the i d 45 HA/d / ...d",
      "relevance_explanation": "This quote explicitly identifies Flublok Quadrivalent (RIV4) as the recombinant influenza vaccine evaluated in the study, confirming its inclusion in the pivotal trial.",
      "source": "completeness_check",
      "metadata": {
        "extraction_round": 2,
        "targeted_aspect": "general"
      }
    },
    {
      "id": "comp_2",
      "quote": "Enrolled and Randomized n=723 vaccine Allocation Flu zone IIV4 n=122 18-44 years: n=57 45-64 years: n=65 Completed day 0 (n=110) 1 month (n=110) and 6 months (n=101) visit Fluarix IIV4 n=120 18-44 years: n=55 45-64 years: n=65 Completed day 0 (n=120) 1 month (n=118) and 6 months (n=107) visit e-enrolled in Year 2 and new enrollees randomized n=684 (139*) ccIIV4 in Year 1 n=214 RIV4 in Year 1 n=152",
      "relevance_explanation": "This quote lists the vaccine allocation for the randomized trial, showing that both Fluarix (quadrivalent standard-dose vaccine) and RIV4 (Flublok Quadrivalent) were included as comparator arms, directly supporting the claim.",
      "source": "completeness_check",
      "metadata": {
        "extraction_round": 2,
        "targeted_aspect": "general"
      }
    },
    {
      "id": "comp_3",
      "quote": "Day 0 1 m 6 m 5 10 Fig. 2 | MN or HI Antibody responses to egg- and cell propagated vaccine viruses at pre vaccination (Day 0), 1 month, and 6 months post vaccination in Year 1. Antibody titers from each of the four vaccine groups were presented as geometric mean titers (GMTs) with 95% confidence interval (CI) respectively for 18\u221244 years and 45\u221264 years age groups. Gray dots represented individual titers. Flu zone IIV4 18\u221244 years: Day 0 (n = 52), 1 m (n = 52), 6 m (n = 47); Flu zone IIV4 4564 years: Day 0 (n = 58), 1 m (n = 58), 6 m (n = 54); Fluarix IIV4 18\u221244 years: Day 0 (n = 55), 1 m (n = 55), 6 m (n = 48); ccIIV4 18\u221244 years: Day 0 (n = 133), 1 m (n = 132), 6 m (n = 124); RIV4 18\u221244 years: Day 0 (n = 98), 1 m (n = 98), 6 m (n = 85);",
      "relevance_explanation": "This quote details the four vaccine groups compared in the trial, including Fluarix IIV4 (quadrivalent standard-dose) and RIV4 (Flublok Quadrivalent), confirming that these two vaccines were directly evaluated against each other.",
      "source": "completeness_check",
      "metadata": {
        "extraction_round": 2,
        "targeted_aspect": "general"
      }
    }
  ],
  "completeness_assessment": {
    "missing_aspects": []
  },
  "model_used": "gpt-4.1"
}